Showing results (101-110 of 566) with videos related to

Sort By:
Pageof 57
Cancer Investigation|June 17, 2006
Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma?V Diehl, K Behringer
Mediterranean Journal of Hematology and Infectious Diseases|November 24, 2011
Therapy-related myeloid neoplasms in patients treated for hodgkin lymphomaD A Eichenauer, A Engert
International Journal of Colorectal Disease|May 17, 2002
The in vitro anti-inflammatory effects of recombinant anti-CD25 immunotoxin on lamina propria T cells of patients with inflammatory bowel disease are not sufficient to cure experimental colitis in miceK Pfister, B M Wittig, B Jüngling, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2010
No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study GroupK Behringer, L Wildt, H Mueller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2005
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II studyA Josting, M Sieniawski, J-P Glossmann, et al.
Der Internist|May 22, 2004
[Malignant lymphoma competence network]A Herrmann-Frank, V Diehl
The Biochemical Journal|December 15, 1987
The autoactivation of factor XII (Hageman factor) induced by low-Mr heparin and dextran sulphate. The effect of the Mr of the activating polyanionM Silverberg, S V Diehl
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2004
Artificial sweeteners--do they bear a carcinogenic risk?M R Weihrauch, V Diehl
International Journal of Cancer|May 16, 1996
Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID miceR Schnell, A A Katouzi, C Linnartz, et al.
Blood|September 10, 1998
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II studyB Coiffier, C Haioun, N Ketterer, et al.
Pageof 57